Company ElsaLys Biotech

ElsaLys Biotech specializes in the design and development of new-generation antibodies intended to modulate the immune systems of patients suffering from cancer or rare blood diseases.

The company has a portfolio of 5 programs in the development phase, including LEUKOTAC® (Inolimomab), an immunotherapy antibody demonstrating a clinical benefit in Phase 3 of a rare disease with a very poor prognosis: acute steroid resistant reaction of the graft against the host.